461 related articles for article (PubMed ID: 8889726)
21. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients--a comparison of meropenem and imipenem/cilastatin. COPD Study Group.
Hamacher J; Vogel F; Lichey J; Kohl FV; Diwok K; Wendel H; Lode H
J Antimicrob Chemother; 1995 Jul; 36 Suppl A():121-33. PubMed ID: 8543488
[TBL] [Abstract][Full Text] [Related]
22. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients.
Shah PM; Heller A; Fuhr HG; Walther F; Halir S; Schaumann R; Böhme A; Jung B; Köhler A; Lips-Schulte C; Stille W
Infection; 1996; 24(6):480-4. PubMed ID: 9007599
[TBL] [Abstract][Full Text] [Related]
23. Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections.
Zanetti G; Harbarth SJ; Trampuz A; Ganeo M; Mosimann F; Chautemps R; Morel P; Lew D; Zimmerli W; Lange J; Glauser M
Int J Antimicrob Agents; 1999 Feb; 11(2):107-13. PubMed ID: 10221413
[TBL] [Abstract][Full Text] [Related]
24. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
Sims M; Mariyanovski V; McLeroth P; Akers W; Lee YC; Brown ML; Du J; Pedley A; Kartsonis NA; Paschke A
J Antimicrob Chemother; 2017 Sep; 72(9):2616-2626. PubMed ID: 28575389
[TBL] [Abstract][Full Text] [Related]
25. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group.
Eklund AE; Nord CE
J Antimicrob Chemother; 1993 Jan; 31 Suppl A():79-85. PubMed ID: 8383657
[TBL] [Abstract][Full Text] [Related]
26. Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. European Study Group.
Norrby SR; Finch RG; Glauser M
J Antimicrob Chemother; 1993 Jun; 31(6):927-37. PubMed ID: 8360130
[TBL] [Abstract][Full Text] [Related]
27. Management of intra-abdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. The Canadian Intra-abdominal Infection Study Group.
Christou NV; Turgeon P; Wassef R; Rotstein O; Bohnen J; Potvin M
Arch Surg; 1996 Nov; 131(11):1193-201. PubMed ID: 8911260
[TBL] [Abstract][Full Text] [Related]
28. Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group.
Donahue PE; Smith DL; Yellin AE; Mintz SJ; Bur F; Luke DR
Am J Surg; 1998 Dec; 176(6A Suppl):53S-61S. PubMed ID: 9935258
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study.
Vazquez JA; González Patzán LD; Stricklin D; Duttaroy DD; Kreidly Z; Lipka J; Sable C
Curr Med Res Opin; 2012 Dec; 28(12):1921-31. PubMed ID: 23145859
[TBL] [Abstract][Full Text] [Related]
30. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
[TBL] [Abstract][Full Text] [Related]
31. Empiric carbapenem monotherapy in pediatric bone marrow transplant recipients.
Nelson WK; Rayback PA; Quinones R; Giller RH
Ann Pharmacother; 2002 Sep; 36(9):1360-5. PubMed ID: 12196052
[TBL] [Abstract][Full Text] [Related]
32. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study.
Zanetti G; Bally F; Greub G; Garbino J; Kinge T; Lew D; Romand JA; Bille J; Aymon D; Stratchounski L; Krawczyk L; Rubinstein E; Schaller MD; Chiolero R; Glauser MP; Cometta A;
Antimicrob Agents Chemother; 2003 Nov; 47(11):3442-7. PubMed ID: 14576100
[TBL] [Abstract][Full Text] [Related]
33. Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections.
Edwards SJ; Emmas CE; Campbell HE
Curr Med Res Opin; 2005 May; 21(5):785-94. PubMed ID: 15969878
[TBL] [Abstract][Full Text] [Related]
34. Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections.
Naber KG; Savov O; Salmen HC
Int J Antimicrob Agents; 2002 Feb; 19(2):95-103. PubMed ID: 11850161
[TBL] [Abstract][Full Text] [Related]
35. Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group.
Mouton YJ; Beuscart C
J Antimicrob Chemother; 1995 Jul; 36 Suppl A():145-56. PubMed ID: 8543490
[TBL] [Abstract][Full Text] [Related]
36. Imipenem/cilastatin for pediatric infections in hospitalized patients.
Nalin DR; Hart CB; Shih WJ; Aziz MA
Scand J Infect Dis Suppl; 1987; 52():56-64. PubMed ID: 3331043
[TBL] [Abstract][Full Text] [Related]
37. The efficacy and safety of imipenem/cilastatin in the treatment of severe bacterial infections.
D'Amato C; Armignacco O; Antonucci G; Bordi E; Bove G; De Carli G; De Mori P; Rosci MA; Visco G
J Chemother; 1990 Apr; 2(2):100-7. PubMed ID: 2193998
[TBL] [Abstract][Full Text] [Related]
38. Meropenem: a review of its use in patients in intensive care.
Hurst M; Lamb HM
Drugs; 2000 Mar; 59(3):653-80. PubMed ID: 10776838
[TBL] [Abstract][Full Text] [Related]
39. Carbapenems in serious infections: a risk-benefit assessment.
Norrby SR
Drug Saf; 2000 Mar; 22(3):191-4. PubMed ID: 10738843
[TBL] [Abstract][Full Text] [Related]
40. Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial.
Geddes A; Thaler M; Schonwald S; Härkönen M; Jacobs F; Nowotny I
J Antimicrob Chemother; 1999 Dec; 44(6):799-810. PubMed ID: 10590282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
